OncoNano Medicine announced that it will present a Trials in Progress poster at the upcoming 2024 ASCO Annual Meeting.

Ozempic, Trulicity and Mounjaro were first approved to treat diabetes, however, in the last three years, the FDA has approved ...

Medetomidine, a synthetic drug used as an animal tranquilizer, is the latest street drug to appear alongside fentanyl. It ...

The centrally acting alpha2-adrenergic agonist allows for nighttime dosing and can be used with stimulants, the drug's ...

Popular weight loss drugs like Wegovy and Ozempic have changed the way many Americans are eating and as people taking these ...

Tokyo, Japan and Cambridge, UK, 30 May 2024 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) today announced that it expects to receive $4.6 ...

A recent study in the Journal of Clinical Medicine found that oral semaglutide significantly improves glycemic control and ...

In the US, GLP-1 agonist drugs like Ozempic and Wegovy are already making people eat fewer calories and fats as they look to ...

Specific demographic, clinical, and financial characteristics are associated with glucagon-like peptide 1 (GLP-1) receptor ...

Merck & Co. agrees to acquire Eyebiotech (EyeBio) for up to $3 billion, a deal that will return the buyer to the eye drug ...

Driven by growing market demand and an improving supply chain, the global weight-loss drug market is expected to hit $150 ...

Merck & Co. is focusing in on eye diseases with the $3 billion acquisition of ophthalmology-focused Eyebiotech. | Merck & Co.